"Designing Growth Strategies is in our DNA"
On March 17, Moderna Therapeutics announced that the company tested their mRNA vaccine candidate against the novel coronavirus on the first patient as part of an early-stage clinical trial. In the past three weeks, many companies- big and small, have entered the fray to develop a vaccine against this growing pandemic. Many large pharmaceutical companies such as Pfizer, GlaxoSmithKline, Johnson & Johnson, and Sanofi have entered into partnerships to develop a vaccine for COVID-19.
As of April 13th, more than 160 COVID-19 vaccine and treatment candidates are under research and development. Although experts believe that it will take at least 12-18 months to develop a vaccine against the novel coronavirus, it has become critical to make one available sooner due to the rapid spread of the outbreak, rising death toll, significant impact on the economy due to the lockdown, and other measures that are being taken to control the infection.
Based on the Johns Hopkins University & Medicine’s Coronavirus Resource Center, there were over 1.9 million cases and around 120,000 deaths attributed to COVID-19 as of 13th April. The first COVID-19 case was reported in the U.S. on 23rd January and the total number of confirmed cases reached over 580,000 as of 13th April.
At present, only the following four vaccine candidates have reached the stage of human trials and hence, the associated companies can be considered as the frontrunners in the race to develop a vaccine against this outbreak.
The pipeline candidates for COVID-19 vaccine include a diverse set of technology platforms – conventional approaches as well as next-generation technologies. The technology platforms that are being evaluated are nucleic acid, virus-like particle, peptide, viral vector, recombinant protein, live attenuated virus, and inactivated virus. The next-generation approaches such as the RNA and DNA vaccines offer benefits such as development speed and ability to scale up the manufacturing/production.
To know how our report can help streamline your business, Speak to Analyst
At present, around 93% of the pipeline candidates for COVID-19 disease are in the preclinical phase. Pharmaceutical companies, government organizations, and other drug manufacturers have sponsored majority of the studies.
Name of Candidate
Self-amplifying RNA vaccine
Imperial College London
The researchers from this college have developed a self-amplifying RNA vaccine within 14 days of receiving the sequence from China.
Animal testing is ongoing, clinical trial is expected in summer 2020.
Plant-based COVID-19 vaccine
The company announced that they have developed coronavirus VLP 20 days after working with the SARS-CoV-2s gene.
Human trial is expected in July or August 2020.
DNA-based vaccine for COVID-19
The company has formed partnership with Applied DNA sciences, which has resulted in the development of four vaccine candidates for COVID 19.
The preclinical results are expected by April 2020 and human trials can be started by fall.
Johnson & Johnson and BARDA
The company has annulled to develop COVID vaccine using ADvac and PER C6 systems.
The human trials are expected by November 2020.
Intranasal COVID-19 vaccine
This is a single dose nasal vaccine developed similarly with the company’s previous influenza vaccine called NasoVAX.
The human trials are expected by August 2020.
The report on ‘COVID-19 Vaccine – Pipeline Review, 2020’ provides a comprehensive overview of the vaccine candidates that are in the R&D pipeline by molecule, recruitment stage, phases, platform, study type, gender, and other factors such as age group and sponsor. The report also provides a thorough analysis of the candidates by clinical trial phases, platform, company, and details such as clinical trial stage, molecule type, mechanism of action, number of recruitment, location, institution, and sponsor for every product in the pipeline.
Products in the preclinical and clinical stage along with the dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview, industry developments, comparison of COVID 19 pandemic with previous pandemics such as SARS, Influenza, and MERS, and steps taken by the government/industry for the development of a vaccine against COVID-19. The report will also throw light on the market indicators such as aging population and prevalence of chronic diseases by country/region.
The report will also provide insights on vaccine candidates that have a higher chance of success based on various factors, such as the stage of development, type, and players involved. Moreover, the report will additionally provide a comprehensive analysis of potential addressable market of these vaccine candidates in terms of value and volume.
The report on ‘COVID-19 Vaccine – Pipeline Review, 2020’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry